Robuta

https://markets.businessinsider.com/news/stocks/illumina-ilmn-receives-a-hold-from-canaccord-genuity-1035796887 Illumina (ILMN) Receives a Hold from Canaccord Genuity | Markets Insider In a report released today, Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Illumina, with a price target of $150.00.Claim 50... canaccord genuityilluminailmnreceiveshold https://www.benzinga.com/analyst-ratings/23/04/32016590/baird-maintains-neutral-rating-for-illumina-heres-what-you-need-to-know Baird Maintains Neutral Rating for Illumina: Here's What You Need To Know - Illumina (NASDAQ:ILMN)... what you need to know https://markets.businessinsider.com/news/stocks/barclays-keeps-their-sell-rating-on-illumina-ilmn-1036021128 Barclays Keeps Their Sell Rating on Illumina (ILMN) | Markets Insider In a report released today, Luke Sergott from Barclays maintained a Sell rating on Illumina, with a price target of $110.00.Claim 30% Off TipRan... barclayskeepssellratingillumina https://markets.businessinsider.com/news/stocks/bank-of-america-securities-reaffirms-their-sell-rating-on-illumina-ilmn-1035887463 Bank of America Securities Reaffirms Their Sell Rating on Illumina (ILMN) | Markets Insider In a report released today, Michael Ryskin from Bank of America Securities maintained a Sell rating on Illumina, with a price target of $85.00.C... bank of america https://omicsomics.blogspot.com/2019/07/uk-cma-ilmnpacb-inconvenience-of-being.html Omics! Omics!: UK CMA & ILMN/PACB: The Inconvenience of Being Earnest. As part two of a yet-to-be-determined number of pieces on the UK's CMA preliminary analysis of the proposed Pacific Biosciences acquisition ... omicsukcmailmnpacb